Zhuo Zhihong, Yu Huimin, Gao Li, Jiang Xingzhi
Ningbo No. 2 Hospital, Ningbo, People's Republic of China.
Minim Invasive Ther Allied Technol. 2019 Dec;28(6):344-350. doi: 10.1080/13645706.2018.1559195. Epub 2019 Mar 25.
To compare the effectiveness of misoprostol administration orally or vaginally for cervical ripening in women before operative hysteroscopy surgery. Two hundred seventy-five women eligible for operative hysteroscopy were recruited for a controlled, blinded, randomized trial. Twenty-two women were excluded from the study. Patients were randomly assigned to take 600 µg of misoprostol or 30 mg vitamin B6 orally or vaginally, respectively, 4-12 h before operative hysteroscopy. Main outcome measures: Extent of cervical diameter before the hysteroscopy procedure, need for further cervical dilatation, degree of ease of cervical dilation, duration of additional cervix dilatation and hysteroscopy procedure, abdominal pain prior to surgical procedure, patients' acceptability, complications and associated side effects during the hysteroscopy procedures. Cervical width in the vaginal and oral misoprostol groups after administration was 7.2 ± 0.9 mm and 7.5 ± 1.4 mm, respectively, a statistically significant difference compared to the control group. The duration required for cervical priming with misoprostol, either vaginally or orally (75 ± 24 s or 82 ± 22 s), was significantly shorter than that of placebo (148 ± 31 s). The effect of cervical dilation with misoprostol was significantly higher in the premenopausal participants. Occurrence of uterine false tract substantially increased in the placebo group. Meanwhile, the risk of side-effects increased in the misoprostol-treated patients compared to the control group. The administration of misoprostol seemed more effective than the control for preoperative cervical priming in menstrual participants. Further large randomized controlled trials are needed to determine whether misoprostol could reduce complications with fewer side-effects and to establish whether misoprostol has a substantial cervical dilation effect on either premenopausal or postmenopausal patients.
比较米索前列醇口服或阴道给药用于宫腔镜手术前女性宫颈成熟的有效性。招募了275名符合宫腔镜手术条件的女性进行一项对照、双盲、随机试验。22名女性被排除在研究之外。患者在宫腔镜手术前4 - 12小时被随机分配分别口服600μg米索前列醇或30mg维生素B6,或阴道给药。主要观察指标:宫腔镜手术前宫颈直径大小、进一步宫颈扩张的需求、宫颈扩张的难易程度、额外宫颈扩张和宫腔镜手术的持续时间、手术前的腹痛、患者的可接受性、宫腔镜手术期间的并发症及相关副作用。给药后,阴道和口服米索前列醇组的宫颈宽度分别为7.2±0.9mm和7.5±1.4mm,与对照组相比有统计学显著差异。米索前列醇经阴道或口服进行宫颈预处理所需的时间(75±24秒或82±22秒)明显短于安慰剂组(148±31秒)。米索前列醇对绝经前参与者的宫颈扩张效果明显更高。安慰剂组子宫假道的发生率大幅增加。同时,与对照组相比,米索前列醇治疗患者的副作用风险增加。对于月经周期正常的参与者,米索前列醇给药在术前宫颈预处理方面似乎比对照组更有效。需要进一步进行大规模随机对照试验,以确定米索前列醇是否能减少并发症且副作用更少,并确定米索前列醇对绝经前或绝经后患者是否有显著的宫颈扩张作用。